Projects per year
Personal profile
Research interests
Dr. Iryna Pinchuk's research focuses on the mechanisms responsible for the dysregulation of mucosal immune responses, in particular those that are involved in inflammatory bowel disease (IBD) and cancer.
Dr. Pinchuk has pioneered the understanding of the immune function of CD90+ stromal cells (CMFs) in colonic mucosa and demonstrated that in normal gastrointestinal mucosa, CMFs play an immunosuppressive role, contributing to the maintenance of the mucosal tolerance. Dr. Pinchuk also reported that IBD- and gastrointestinal-cancer-derived CMFs have altered tolerogenic function.
Her major study focus is to understand both the interplay between innate and adaptive cells during IBD and cancer development and progression as well as how microbiota modulate these interactions.
Dr. Pinchuk has substantial expertise in the area of human and rodent gastrointestinal mucosal immune responses and more than 15 years of experience in the areas of immunology, cell biology, microbiology and gastrointestinal research.
She holds a patent and has published numerous peer-reviewed articles and two book chapters in the field of immunology, cell biology and microbiology.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
-
Targeting MK2 for Crohn's Disease
Pinchuk, I. (PI)
Congressionally Directed Medical Research Programs
5/1/22 → 3/31/26
Project: Research project
-
Regulatory role of CD90+ stromal cells in Th1/Th17 activity in Crohn's Disease
Pinchuk, I. (PI)
National Institute of Diabetes and Digestive and Kidney Diseases
7/1/14 → 6/30/19
Project: Research project
-
MK2 Inhibition in CD4+T Cells Protects Against IFNγand IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models
Howe, C. S., Chulkina, M., Syrcle, R., McAninch, C., McAninch, S., Pinchuk, I. V. & Beswick, E. J., Jun 1 2025, In: Inflammatory bowel diseases. 31, 6, p. 1664-1676 13 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
MR2938 relieves DSS-induced colitis in mice through inhibiting NF-κB signaling and improving epithelial barrier
Lv, L., Maimaitiming, M., Xia, S., Yang, J., Zhang, T., Wang, Y., Li, X., Pinchuk, I., Wang, P., Wang, C. Y. & Liu, Z., 2025, (Accepted/In press) In: Marine Life Science and Technology. a002907.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
MyD88-mediated signaling in intestinal fibroblasts regulates macrophage antimicrobial defense and prevents dysbiosis in the gut
Chulkina, M., Tran, H., Uribe, G., McAninch, S. B., McAninch, C., Seideneck, A., He, B., Lanza, M., Khanipov, K., Golovko, G., Powell, D. W., Davenport, E. R. & Pinchuk, I. V., May 27 2025, In: Cell Reports. 44, 5, 115553.Research output: Contribution to journal › Article › peer-review
Open Access -
Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease
Ma, Z., McAninch, S., Liu, Z., Zhang, C., Chen, H., He, J., Yang, W., Panganiban, R. P., Cong, Y., Yochum, G., Brasier, A. R., Pinchuk, I. V., Tian, B. & Zhou, J., Apr 11 2025, In: ACS Pharmacology and Translational Science. 8, 4, p. 1152-1167 16 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease
Ma, Z., Bolinger, A. A., Pinchuk, I. V., Tian, B. & Zhou, J., Jan 2024, Emerging Therapeutic Targets and Drug Delivery Approaches in IBD. Selaru, F. M. & Peters, D. E. (eds.). Academic Press Inc., p. 203-236 34 p. (Advances in Pharmacology; vol. 101).Research output: Chapter in Book/Report/Conference proceeding › Chapter
2 Scopus citations